Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cannabinoid study reveals how the brain handles fear in PTSD

NCT ID NCT02069366

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how a single dose of dronabinol (a synthetic cannabinoid) affects fear-related brain activity in people with PTSD, trauma-exposed individuals without PTSD, and healthy controls. Using brain scans, researchers measured how the drug influences fear extinction circuits. The goal is to better understand PTSD and potentially develop new treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dronabinol (a synthetic cannabinoid)
What this could lead to
If successful, this research could point toward new treatments for anxiety and fear-based disorders like PTSD.
What could go wrong
This is a small, early-stage study focused on understanding brain mechanisms, not testing a treatment. The drug is given only once, so results may not apply to real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

86 people

The number who actually took part.

Started

Nov 2014

Finished

Dec 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for All Participants: * Able to give informed consent * Physically and neurologically healthy \[confirmed by a comprehensive medical history\] * Age between 21-45 years old * Right-handed Inclusion Criteria for Participants with PTSD: * Current PTSD diagnosis \[related to civilian trauma\] Inclusion Criteria for Trauma-Exposed Participants without PTSD: * Experience with a civilian trauma without a PTSD diagnosis * Free of a lifetime Axis I or Axis II diagnosis Inclusion Criteria for Non-Trauma-Exposed Healthy Participants: * Free of a lifetime Axis I or Axis II diagnosis Exclusion Criteria for All Participants: * Clinically significant medical or neurological condition * Less than a high school education * Lack of fluency in English * Night shift work * Currently pregnant; planning pregnancy; or lactating * Unwilling/unable to sign informed consent document * Inability to tolerate small, enclosed spaces without anxiety (e.g. claustrophobia) * Left-handed * Presence of ferrous-containing metals within the body (e.g., aneurysm clips, shrapnel/retained particles) * Under 21 or over 45 years of age * Anticipation of a required drug test in the 4 weeks following study participation * Positive urine drug screen and/or alcohol breathalyzer * Current or past allergic or adverse reaction or known sensitivity to cannabinoid-like substances \[dronabinol/marijuana/cannabis/thc, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide\] * Participation in an experiment involving white noise bursts or shocks in the last 6 months Exclusion Criteria for Participants with PTSD: * Primary comorbid anxiety disorder (defined by which disorder was the more debilitating and clinically salient) * Life history of bipolar disorder, schizophrenia, or presence of an organic mental syndrome, mental retardation, or pervasive developmental disorder * Current or in the past 6 months alcohol/drug abuse of dependence * Current or in the past 6 months major depressive disorder * Current suicidal ideation * Diagnosis of an Axis II personality disorder * Concomitant treatments with psychotropic/psychoactive medication \[including beta-adrenergic blockers, selective serotonin reuptake inhibitor (SSRI), benzodiazepines, tricyclic or monoamine oxidase inhibitor (MAOI) antidepressants, lithium, antiepileptic/anticonvulsants, neuroleptics/antipsychotics, etc.) or in the past two weeks \[8 weeks for fluoxetine and 4 weeks for MAOIs) before screening (Visit 1) * currently receiving exposure-based therapy for PTSD Exclusion Criteria for Trauma-Exposed Participants without PTSD and Non-Trauma Exposed Healthy Participants: * Current or past Axis I psychiatric disorder \[including alcohol/substance abuse of dependence disorder\]

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post traumatic stress disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Eugene Applebaum College of Pharmacy and Health Sciences

    Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.